SlideShare a Scribd company logo
1 of 70
Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72
Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72
Available screening and diagnostic methods areAvailable screening and diagnostic methods are
insufficient to identify the victims before the eventinsufficient to identify the victims before the event
occurs.occurs.
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are known
heart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are known
heart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are known
heart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are known
heart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are knownl risk factors are known
heart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
http://www.aeha.org/
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
2004
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
↑↑BPBP
½½
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
↑↑CholChol
1/31/3
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
SmokeSmoke
1/51/5
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
ConventionalConventional
risk factorsrisk factors
75%75%
Lancet 2004
364:937-52
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are knownl risk factors are known
heart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are knownl risk factors are known
heart attacks are preventableheart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are knownl risk factors are known
heart attacks are preventableheart attacks are preventable
ins killer #1, + severe disability
onal approach has failed!
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are knownl risk factors are known
heart attacks are preventableheart attacks are preventable
ins killer #1,ins killer #1, + severe disability+ severe disability
onal approach has failed!
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html
Women ~ MenWomen ~ Men
AHA Statistics – 2005 Update. http://www.americanheart.org/downloadable/heart/1105390918119HDSStats2005Update.pdf
38% of all deaths in the US caused by CVD
Heart attack caused by atherosclerosis
Eradication: dream or reality?Eradication: dream or reality?
l risk factors are knownl risk factors are known
heart attacks are preventableheart attacks are preventable
ins killer #1,ins killer #1, + severe disability+ severe disability
onal approach has failed!
Why?
Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72
Available screening and diagnostic methods areAvailable screening and diagnostic methods are
insufficient to identify the victims before the eventinsufficient to identify the victims before the event
occurs.occurs.
Milestone
Framingham’s risk factor conceptFramingham’s risk factor concept
Milestone
Framingham’s risk factor conceptFramingham’s risk factor concept
Milestone
Framingham’s risk factor conceptFramingham’s risk factor concept
Causal factors
versus
predictors
Wald et al. Lancet 1994;343:75-9
~80%
overlap
… considerable overlap …
Relative odds
individual at the 90individual at the 90thth
centilecentile
vsvs
individual at the 10individual at the 10thth
(RO(RO10-9010-90))
High
risk
Low
risk
~80%
overlap
Wald et al. Lancet 1994;343:75-9
Relative odds
individual at the 90individual at the 90thth
centilecentile
vsvs
individual at the 10individual at the 10thth
(RO(RO10-9010-90))
RO10-90 = 13
poor screening testpoor screening test
High
risk
Low
risk
~80%
overlap
Wald et al. Lancet 1994;343:75-9
Relative distributions
of risk factors
in men who subsequently died
of IHD and in men who did not.
Gaussian distribution fitted to
data from a cohort of
22 000 men22 000 men followedfollowed
prospectively for 10 yearsprospectively for 10 years
(the BUPA study) Wald, Law. BMJ 2003;326:1419-23
Men
CHD risk prediction (& treatment)
Framingham risk factor scoringFramingham risk factor scoring
Predictive accuracyPredictive accuracy
•.90-1 = excellent.90-1 = excellent
•.80-.90 = good.80-.90 = good
•.70-.80 = fair.70-.80 = fair
•.60-.70 = poor.60-.70 = poor
•.50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
1
D’Agostino et al. JAMA 2001
AHA Statistical Fact Sheet 2005.
Framingham1
M: 0.79; W: 0.83M: 0.79; W: 0.83
Framingham Risk Factor Scoring
discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
Honolulu1
0.720.72
New York2
0.680.68
1
D’Agostino et al. JAMA 2001; 2
Arad et al. JACC 2005
AHA Statistical Fact Sheet 2005.
Physicians' Health Study1
0.630.63
Cardiovascular Health Study1
(NC, CA, MD, PA)
M: 0.63; W: 0.66M: 0.63; W: 0.66
Framingham1
M: 0.79; W: 0.83M: 0.79; W: 0.83
Framingham Risk Factor Scoring
discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
Predictive accuracyPredictive accuracy
•.90-1 = excellent.90-1 = excellent
•.80-.90 = good.80-.90 = good
•.70-.80 = fair.70-.80 = fair
•.60-.70 = poor.60-.70 = poor
•.50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
AHA Statistical Fact Sheet 2005.
http://www.americanheart.org/downloadable/heart/1104962839076FS21DR5NEW.pdf
Death Rates
CHDCHD
AHA Statistical Fact Sheet 2005.
http://www.americanheart.org/downloadable/heart/1104962839076FS21DR5NEW.pdf
Death Rates
StrokeStroke
Framingham Risk Factor Scoring
discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
Predictive accuracyPredictive accuracy
• .90-1 = excellent.90-1 = excellent
• .80-.90 = good.80-.90 = good
• .70-.80 = fair.70-.80 = fair
• .60-.70 = poor.60-.70 = poor
• .50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
UK1
0.620.62
1
Cooper et al, Ath 2005
2
Danesh et al. NEJM 2004
3
Ferrario et al. IJE 2005
4
Thomsen et al. IJE 2002
5
Hense et al. EHJ 2003
Iceland2
0.640.64
Denmark4
0.750.75
GermanyMünster5
M: 0.73; W: 0.77M: 0.73; W: 0.77
Framingham Risk Factor Scoring
discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
Predictive accuracyPredictive accuracy
• .90-1 = excellent.90-1 = excellent
• .80-.90 = good.80-.90 = good
• .70-.80 = fair.70-.80 = fair
• .60-.70 = poor.60-.70 = poor
• .50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
Belfast1
0.660.66
France1
0.680.68
Italy3
0.720.72
UK1
0.620.62
PROCAM in UK1
0.630.63
1
Cooper et al, Ath 2005
2
Danesh et al. NEJM 2004
3
Ferrario et al. IJE 2005
4
Thomsen et al. IJE 2002
5
Hense et al. EHJ 2003
UK in UK1
0.640.64
Iceland2
0.640.64
Italy3
0.720.72
Denmark4
0.750.75
GermanyMünster5
M: 0.73; W: 0.77M: 0.73; W: 0.77
Framingham Risk Factor Scoring
discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
Predictive accuracyPredictive accuracy
• .90-1 = excellent.90-1 = excellent
• .80-.90 = good.80-.90 = good
• .70-.80 = fair.70-.80 = fair
• .60-.70 = poor.60-.70 = poor
• .50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
Belfast1
0.660.66
France1
0.680.68
PROCAM in It3
: 0.740.74
CUORE in It3
: 0.740.74
Atherosclerosis 2005;181:93-100
Atherosclerosis 2005;181:93-100
Predictive accuracy of risk factor scoring
PROCAM: 0.63; Framigham = 0.62PROCAM: 0.63; Framigham = 0.62
Predictive accuracyPredictive accuracy
• .90-1 = excellent.90-1 = excellent
• .80-.90 = good.80-.90 = good
• .70-.80 = fair.70-.80 = fair
• .60-.70 = poor.60-.70 = poor
• .50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
Hard to improve the predictive accuracy
by adding novel factors
Atherosclerosis 2005;181:93-100
Risk prediction by risk factor scoring
considerable overlap, not useful for screeningconsiderable overlap, not useful for screening
Atherosclerosis 2005;181:93-100
Framingham Risk Factor Scoring
discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
China
M: 0.74; W: 0.76M: 0.74; W: 0.76
Liu et al. JAMA 2004;291:2591-9
Predictive accuracyPredictive accuracy
• .90-1 = excellent.90-1 = excellent
• .80-.90 = good.80-.90 = good
• .70-.80 = fair.70-.80 = fair
• .60-.70 = poor.60-.70 = poor
• .50-.60 = fail.50-.60 = fail
http://gim.unmc.edu/dxtests/ROC3.htm
Framingham Risk Factor Scoring
hard endpoints: predicted vs observedhard endpoints: predicted vs observed
Liu et al. JAMA 2004;291:2591-9
Hard endpoints/10-yHard endpoints/10-y 20%
3%
China
China
Liu et al. JAMA 2004;291:2591-9
Framingham Risk Factor Scoring
hard endpoints: predicted vs observedhard endpoints: predicted vs observed
Risk in Europe based on European populations
susceptibility to causal risk factors: north vs southsusceptibility to causal risk factors: north vs south







  
Susceptibility to disease
similar risk factor exposuresimilar risk factor exposure →→ different risk of IHDdifferent risk of IHD
NY < MA
South < North
China <<< Framingham
Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72
Available screening and diagnostic methods areAvailable screening and diagnostic methods are
insufficient to identify the victims before the eventinsufficient to identify the victims before the event
occurs.occurs.
Best Marker of Susceptibility to CHD
prevalent arterial diseaseprevalent arterial disease
CHD risk equivalentsCHD risk equivalents
NCEP ATP III
2002
AEHAAEHA
Atherosclerosis Test
Negative Positive
No Risk Factors + Risk Factors
Step 1
Test for
Presence of the
Disease
Step 2
Stratify based on the
Severity of the Disease and
Presence of Risk Factors
Step 3
Treat based on
the Level of
Risk
Lower
Risk
Moderate
Risk
Moderately
High Risk
High
Risk
Very
High Risk
Apparently Healthy At-Risk Population
The 1st S.H.A.P.E. Guideline
Towards the National Screening for Heart Attack Prevention and Education (SHAPE) Program
Conceptual Flow Chart
<75th
Percentile
75th-90th
Percentile
≥90th
Percentile
+ ++ +++
JACC 2005;46:173-5
The St. Francis Heart Study
The St. Francis Heart Study
fewer hard endpoints than predictedfewer hard endpoints than predicted (Framingham)(Framingham)
Grundy SM. JACC 2005;46:173-5
Grundy SM. JACC 2005;46:173-5
The St. Francis Heart Study
more soft than hard endpointsmore soft than hard endpoints
Grundy SM. JACC 2005;46:173-5
Risk prediction in clinical practice
? current risk categories retained, all events included ?? current risk categories retained, all events included ?
Grundy SM. JACC 2005;46:173-5
Risk prediction in clinical practice
? current risk categories retained, all events included ?? current risk categories retained, all events included ?
Grundy SM. JACC 2005;46:173-5
Risk prediction in clinical practice
? current risk categories retained, all events included ?? current risk categories retained, all events included ?
Atherosclerosis Test
Negative Positive
No Risk Factors + Risk Factors
Step 1
Test for
Presence of the
Disease
Step 2
Stratify based on the
Severity of the Disease and
Presence of Risk Factors
Step 3
Treat based on
the Level of
Risk
Lower
Risk
Moderate
Risk
Moderately
High Risk
High
Risk
Very
High Risk
Apparently Healthy At-Risk Population
The 1st S.H.A.P.E. Guideline
Towards the National Screening for Heart Attack Prevention and Education (SHAPE) Program
Conceptual Flow Chart
<75th
Percentile
75th-90th
Percentile
≥90th
Percentile
+ ++ +++
http://www.aeha.org

More Related Content

Viewers also liked

Viewers also liked (16)

3rd vulnerable plaque rumberger 3 16-02 4
3rd vulnerable plaque rumberger 3 16-02 43rd vulnerable plaque rumberger 3 16-02 4
3rd vulnerable plaque rumberger 3 16-02 4
 
Lecture vienna september 16 2005
Lecture vienna september 16 2005Lecture vienna september 16 2005
Lecture vienna september 16 2005
 
253 endothelial dysfunction
253 endothelial dysfunction253 endothelial dysfunction
253 endothelial dysfunction
 
Fuster aha-2005-dallas-biomarkers,
Fuster  aha-2005-dallas-biomarkers,Fuster  aha-2005-dallas-biomarkers,
Fuster aha-2005-dallas-biomarkers,
 
New advances in thermography
New advances in thermographyNew advances in thermography
New advances in thermography
 
How the world dies today
How the world dies todayHow the world dies today
How the world dies today
 
240 spatial encoding
240 spatial encoding240 spatial encoding
240 spatial encoding
 
101 adventitial fat macrophage density
101 adventitial fat macrophage density101 adventitial fat macrophage density
101 adventitial fat macrophage density
 
Dog's heart
Dog's heartDog's heart
Dog's heart
 
For elring 2
For elring 2For elring 2
For elring 2
 
Macrophage apoptosis
Macrophage apoptosisMacrophage apoptosis
Macrophage apoptosis
 
Non invasive detection of vulnerable plaque 2
Non invasive detection of vulnerable plaque 2Non invasive detection of vulnerable plaque 2
Non invasive detection of vulnerable plaque 2
 
246 recombinant apolipoprotein ai milano
246 recombinant apolipoprotein ai milano246 recombinant apolipoprotein ai milano
246 recombinant apolipoprotein ai milano
 
Nmr relaxation times
Nmr relaxation timesNmr relaxation times
Nmr relaxation times
 
Nilsson
NilssonNilsson
Nilsson
 
Koenig aeha2005 short
Koenig aeha2005 shortKoenig aeha2005 short
Koenig aeha2005 short
 

Similar to Falk, shape aha 05, final

Nurs212 Code Brain Attack
Nurs212 Code Brain AttackNurs212 Code Brain Attack
Nurs212 Code Brain Attackernursediane
 
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaDr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaSociedad Española de Cardiología
 
Cardiovascular risk factors in rheumatology patients
Cardiovascular risk factors in rheumatology patientsCardiovascular risk factors in rheumatology patients
Cardiovascular risk factors in rheumatology patientsMyanmarRheumatology
 
136 framingham model and coronary events
136 framingham model and coronary events136 framingham model and coronary events
136 framingham model and coronary eventsSHAPE Society
 

Similar to Falk, shape aha 05, final (20)

Falk, final talk
Falk, final talkFalk, final talk
Falk, final talk
 
Shape aha 2005
Shape   aha 2005Shape   aha 2005
Shape aha 2005
 
Nurs212 Code Brain Attack
Nurs212 Code Brain AttackNurs212 Code Brain Attack
Nurs212 Code Brain Attack
 
Aeha cea- shaw
Aeha   cea- shawAeha   cea- shaw
Aeha cea- shaw
 
Rumberger 2nd vp symposium 3 6 04
Rumberger 2nd vp symposium 3 6 04Rumberger 2nd vp symposium 3 6 04
Rumberger 2nd vp symposium 3 6 04
 
Dr falk's slides part i
Dr falk's slides  part iDr falk's slides  part i
Dr falk's slides part i
 
Dr selim updates on osteoporosis
Dr selim updates on osteoporosisDr selim updates on osteoporosis
Dr selim updates on osteoporosis
 
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaDr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
 
Dr falk's slides part ii
Dr falk's slides  part iiDr falk's slides  part ii
Dr falk's slides part ii
 
Harvey hecht md aeha sat
Harvey hecht md aeha satHarvey hecht md aeha sat
Harvey hecht md aeha sat
 
Cardiovascular risk factors in rheumatology patients
Cardiovascular risk factors in rheumatology patientsCardiovascular risk factors in rheumatology patients
Cardiovascular risk factors in rheumatology patients
 
Economics of screening for atherosclerosis final
Economics of screening for atherosclerosis finalEconomics of screening for atherosclerosis final
Economics of screening for atherosclerosis final
 
Rumberger
RumbergerRumberger
Rumberger
 
136 framingham model and coronary events
136 framingham model and coronary events136 framingham model and coronary events
136 framingham model and coronary events
 
Dr koenig
Dr koenigDr koenig
Dr koenig
 
136 framingham model and coronary events
136 framingham model and coronary events136 framingham model and coronary events
136 framingham model and coronary events
 
Vp meeting orlando2003_new template
Vp meeting orlando2003_new templateVp meeting orlando2003_new template
Vp meeting orlando2003_new template
 
Cancer undefeated2
Cancer undefeated2Cancer undefeated2
Cancer undefeated2
 
Aeha2004 crp lppla2newtemplate
Aeha2004 crp lppla2newtemplateAeha2004 crp lppla2newtemplate
Aeha2004 crp lppla2newtemplate
 

More from Society for Heart Attack Prevention and Eradication

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 
Vpiii lobby-02
Vpiii lobby-02Vpiii lobby-02
Vpiii lobby-02
 

Recently uploaded

Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 

Recently uploaded (20)

Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 

Falk, shape aha 05, final

  • 1.
  • 2. Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72
  • 3. Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72 Available screening and diagnostic methods areAvailable screening and diagnostic methods are insufficient to identify the victims before the eventinsufficient to identify the victims before the event occurs.occurs.
  • 4. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality?
  • 5. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are known heart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 6. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are known heart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 7. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are known heart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 8. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are known heart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 9. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are knownl risk factors are known heart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 20. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are knownl risk factors are known heart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 21. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are knownl risk factors are known heart attacks are preventableheart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 22.
  • 23. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are knownl risk factors are known heart attacks are preventableheart attacks are preventable ins killer #1, + severe disability onal approach has failed!
  • 24. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are knownl risk factors are known heart attacks are preventableheart attacks are preventable ins killer #1,ins killer #1, + severe disability+ severe disability onal approach has failed!
  • 28. AHA Statistics – 2005 Update. http://www.americanheart.org/downloadable/heart/1105390918119HDSStats2005Update.pdf 38% of all deaths in the US caused by CVD
  • 29. Heart attack caused by atherosclerosis Eradication: dream or reality?Eradication: dream or reality? l risk factors are knownl risk factors are known heart attacks are preventableheart attacks are preventable ins killer #1,ins killer #1, + severe disability+ severe disability onal approach has failed! Why?
  • 30. Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72 Available screening and diagnostic methods areAvailable screening and diagnostic methods are insufficient to identify the victims before the eventinsufficient to identify the victims before the event occurs.occurs.
  • 31. Milestone Framingham’s risk factor conceptFramingham’s risk factor concept
  • 32. Milestone Framingham’s risk factor conceptFramingham’s risk factor concept
  • 33. Milestone Framingham’s risk factor conceptFramingham’s risk factor concept Causal factors versus predictors
  • 34.
  • 35. Wald et al. Lancet 1994;343:75-9 ~80% overlap … considerable overlap …
  • 36. Relative odds individual at the 90individual at the 90thth centilecentile vsvs individual at the 10individual at the 10thth (RO(RO10-9010-90)) High risk Low risk ~80% overlap Wald et al. Lancet 1994;343:75-9
  • 37. Relative odds individual at the 90individual at the 90thth centilecentile vsvs individual at the 10individual at the 10thth (RO(RO10-9010-90)) RO10-90 = 13 poor screening testpoor screening test High risk Low risk ~80% overlap Wald et al. Lancet 1994;343:75-9
  • 38.
  • 39.
  • 40. Relative distributions of risk factors in men who subsequently died of IHD and in men who did not. Gaussian distribution fitted to data from a cohort of 22 000 men22 000 men followedfollowed prospectively for 10 yearsprospectively for 10 years (the BUPA study) Wald, Law. BMJ 2003;326:1419-23
  • 41. Men CHD risk prediction (& treatment) Framingham risk factor scoringFramingham risk factor scoring
  • 42.
  • 43. Predictive accuracyPredictive accuracy •.90-1 = excellent.90-1 = excellent •.80-.90 = good.80-.90 = good •.70-.80 = fair.70-.80 = fair •.60-.70 = poor.60-.70 = poor •.50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm 1 D’Agostino et al. JAMA 2001 AHA Statistical Fact Sheet 2005. Framingham1 M: 0.79; W: 0.83M: 0.79; W: 0.83 Framingham Risk Factor Scoring discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve
  • 44. Honolulu1 0.720.72 New York2 0.680.68 1 D’Agostino et al. JAMA 2001; 2 Arad et al. JACC 2005 AHA Statistical Fact Sheet 2005. Physicians' Health Study1 0.630.63 Cardiovascular Health Study1 (NC, CA, MD, PA) M: 0.63; W: 0.66M: 0.63; W: 0.66 Framingham1 M: 0.79; W: 0.83M: 0.79; W: 0.83 Framingham Risk Factor Scoring discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve Predictive accuracyPredictive accuracy •.90-1 = excellent.90-1 = excellent •.80-.90 = good.80-.90 = good •.70-.80 = fair.70-.80 = fair •.60-.70 = poor.60-.70 = poor •.50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm
  • 45. AHA Statistical Fact Sheet 2005. http://www.americanheart.org/downloadable/heart/1104962839076FS21DR5NEW.pdf Death Rates CHDCHD
  • 46. AHA Statistical Fact Sheet 2005. http://www.americanheart.org/downloadable/heart/1104962839076FS21DR5NEW.pdf Death Rates StrokeStroke
  • 47. Framingham Risk Factor Scoring discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve Predictive accuracyPredictive accuracy • .90-1 = excellent.90-1 = excellent • .80-.90 = good.80-.90 = good • .70-.80 = fair.70-.80 = fair • .60-.70 = poor.60-.70 = poor • .50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm
  • 48. UK1 0.620.62 1 Cooper et al, Ath 2005 2 Danesh et al. NEJM 2004 3 Ferrario et al. IJE 2005 4 Thomsen et al. IJE 2002 5 Hense et al. EHJ 2003 Iceland2 0.640.64 Denmark4 0.750.75 GermanyMünster5 M: 0.73; W: 0.77M: 0.73; W: 0.77 Framingham Risk Factor Scoring discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve Predictive accuracyPredictive accuracy • .90-1 = excellent.90-1 = excellent • .80-.90 = good.80-.90 = good • .70-.80 = fair.70-.80 = fair • .60-.70 = poor.60-.70 = poor • .50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm Belfast1 0.660.66 France1 0.680.68 Italy3 0.720.72
  • 49. UK1 0.620.62 PROCAM in UK1 0.630.63 1 Cooper et al, Ath 2005 2 Danesh et al. NEJM 2004 3 Ferrario et al. IJE 2005 4 Thomsen et al. IJE 2002 5 Hense et al. EHJ 2003 UK in UK1 0.640.64 Iceland2 0.640.64 Italy3 0.720.72 Denmark4 0.750.75 GermanyMünster5 M: 0.73; W: 0.77M: 0.73; W: 0.77 Framingham Risk Factor Scoring discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve Predictive accuracyPredictive accuracy • .90-1 = excellent.90-1 = excellent • .80-.90 = good.80-.90 = good • .70-.80 = fair.70-.80 = fair • .60-.70 = poor.60-.70 = poor • .50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm Belfast1 0.660.66 France1 0.680.68 PROCAM in It3 : 0.740.74 CUORE in It3 : 0.740.74
  • 51. Atherosclerosis 2005;181:93-100 Predictive accuracy of risk factor scoring PROCAM: 0.63; Framigham = 0.62PROCAM: 0.63; Framigham = 0.62 Predictive accuracyPredictive accuracy • .90-1 = excellent.90-1 = excellent • .80-.90 = good.80-.90 = good • .70-.80 = fair.70-.80 = fair • .60-.70 = poor.60-.70 = poor • .50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm
  • 52. Hard to improve the predictive accuracy by adding novel factors Atherosclerosis 2005;181:93-100
  • 53. Risk prediction by risk factor scoring considerable overlap, not useful for screeningconsiderable overlap, not useful for screening Atherosclerosis 2005;181:93-100
  • 54. Framingham Risk Factor Scoring discrimination between +/- CHD events: AUROC curvediscrimination between +/- CHD events: AUROC curve China M: 0.74; W: 0.76M: 0.74; W: 0.76 Liu et al. JAMA 2004;291:2591-9 Predictive accuracyPredictive accuracy • .90-1 = excellent.90-1 = excellent • .80-.90 = good.80-.90 = good • .70-.80 = fair.70-.80 = fair • .60-.70 = poor.60-.70 = poor • .50-.60 = fail.50-.60 = fail http://gim.unmc.edu/dxtests/ROC3.htm
  • 55. Framingham Risk Factor Scoring hard endpoints: predicted vs observedhard endpoints: predicted vs observed Liu et al. JAMA 2004;291:2591-9 Hard endpoints/10-yHard endpoints/10-y 20% 3% China
  • 56. China Liu et al. JAMA 2004;291:2591-9 Framingham Risk Factor Scoring hard endpoints: predicted vs observedhard endpoints: predicted vs observed
  • 57. Risk in Europe based on European populations susceptibility to causal risk factors: north vs southsusceptibility to causal risk factors: north vs south          
  • 58. Susceptibility to disease similar risk factor exposuresimilar risk factor exposure →→ different risk of IHDdifferent risk of IHD NY < MA South < North China <<< Framingham
  • 59. Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72Circulation. VP Consensus Document. 2003 Oct 7;108:1664-72 Available screening and diagnostic methods areAvailable screening and diagnostic methods are insufficient to identify the victims before the eventinsufficient to identify the victims before the event occurs.occurs.
  • 60. Best Marker of Susceptibility to CHD prevalent arterial diseaseprevalent arterial disease CHD risk equivalentsCHD risk equivalents NCEP ATP III 2002
  • 62. Atherosclerosis Test Negative Positive No Risk Factors + Risk Factors Step 1 Test for Presence of the Disease Step 2 Stratify based on the Severity of the Disease and Presence of Risk Factors Step 3 Treat based on the Level of Risk Lower Risk Moderate Risk Moderately High Risk High Risk Very High Risk Apparently Healthy At-Risk Population The 1st S.H.A.P.E. Guideline Towards the National Screening for Heart Attack Prevention and Education (SHAPE) Program Conceptual Flow Chart <75th Percentile 75th-90th Percentile ≥90th Percentile + ++ +++
  • 63. JACC 2005;46:173-5 The St. Francis Heart Study
  • 64. The St. Francis Heart Study fewer hard endpoints than predictedfewer hard endpoints than predicted (Framingham)(Framingham) Grundy SM. JACC 2005;46:173-5
  • 65. Grundy SM. JACC 2005;46:173-5 The St. Francis Heart Study more soft than hard endpointsmore soft than hard endpoints
  • 66. Grundy SM. JACC 2005;46:173-5 Risk prediction in clinical practice ? current risk categories retained, all events included ?? current risk categories retained, all events included ?
  • 67. Grundy SM. JACC 2005;46:173-5 Risk prediction in clinical practice ? current risk categories retained, all events included ?? current risk categories retained, all events included ?
  • 68. Grundy SM. JACC 2005;46:173-5 Risk prediction in clinical practice ? current risk categories retained, all events included ?? current risk categories retained, all events included ?
  • 69. Atherosclerosis Test Negative Positive No Risk Factors + Risk Factors Step 1 Test for Presence of the Disease Step 2 Stratify based on the Severity of the Disease and Presence of Risk Factors Step 3 Treat based on the Level of Risk Lower Risk Moderate Risk Moderately High Risk High Risk Very High Risk Apparently Healthy At-Risk Population The 1st S.H.A.P.E. Guideline Towards the National Screening for Heart Attack Prevention and Education (SHAPE) Program Conceptual Flow Chart <75th Percentile 75th-90th Percentile ≥90th Percentile + ++ +++